On March 20, 2026, we detected 1 new cluster buy including a $1M purchase in $CRM by 2 insiders, and 5 notable insider purchases. Pale Fire Capital SE (10% Owner) bought $9.1M of $PHR. Data sourced from SEC Form 4 filings analyzed by Average Insider.
⚠️ For information purposes only. This information is provided for informational purposes only and does not constitute investment advice, financial advice, trading advice, or any other type of advice. All investments carry risk, including the potential loss of principal. Past performance is not indicative of future results. You should consult with a qualified financial advisor, accountant, or other professional before making any investment decisions. The information contained in this newsletter is not intended to be a substitute for professional financial advice.
📊 Insider Trading Insights — March 20, 2026
Tracking insider purchases and cluster buys over the past 7 days. Insider buying can indicate confidence in a company's future, while cluster buys (multiple insiders buying around the same time) are particularly noteworthy signals.
🔥 Cluster Buys
| | |
| Date Range Mar 18, 2026 – Mar 19, 2026 | |
👥 Participant Details
Kirk David Blair Director | 2,570 shares $500,178 @ $194.62/share 2026-03-18T00:00:00 |
P&L: +0.2% (+$946) | ALBER LAURA Director | 491 shares $95,519 @ $194.54/share 2026-03-19T00:00:00 |
P&L: +0.2% (+$221) |
ALBER LAURA Director | 2,080 shares $404,747 @ $194.59/share 2026-03-19T00:00:00 |
P&L: +0.2% (+$832) | |
📊 Valuation & Analyst Info
Fair Value: $250.14 (+28.3% undervalued vs current price)
P/E Ratio: 27.0 (0.6x below Software - Application avg (65.6)) (0.4x below Technology avg (43.8))
Analyst Consensus: Buy
Price Target: $287.00 (Low: $235.00 | High: $400.00 | Median: $270.00)
📰 Recent News (Last 7 Days)
💰 Individual Insider Buys
Transaction Date Mar 19, 2026 | | |
| | |
📊 Valuation & Analyst Info
Fair Value: $-67.25 (-671.4% overvalued vs current price)
P/E Ratio: -28.0
Analyst Consensus: Buy
Price Target: $27.50 (Low: $22.00 | High: $33.00 | Median: $27.50)
📰 Recent News (Last 7 Days)
📈 Recent Earnings: 2026-05-26
Transaction Date Mar 18, 2026 | | |
| | |
📊 Valuation & Analyst Info
Fair Value: $-67.25 (-671.4% overvalued vs current price)
P/E Ratio: -28.0
Analyst Consensus: Buy
Price Target: $27.50 (Low: $22.00 | High: $33.00 | Median: $27.50)
📰 Recent News (Last 7 Days)
📈 Recent Earnings: 2026-05-26
Transaction Date Mar 18, 2026 | | |
| | |
📊 Valuation & Analyst Info
Fair Value: $111.38 (+390.2% undervalued vs current price)
P/E Ratio: -210.2
Analyst Consensus: Hold
Price Target: $50.20 (Low: $35.00 | High: $62.00 | Median: $56.00)
📰 Recent News (Last 7 Days)
📈 Recent Earnings: 2026-05-05
Transaction Date Mar 17, 2026 | | |
| | |
📊 Valuation & Analyst Info
Fair Value: $-67.25 (-671.4% overvalued vs current price)
P/E Ratio: -28.0
Analyst Consensus: Buy
Price Target: $27.50 (Low: $22.00 | High: $33.00 | Median: $27.50)
📰 Recent News (Last 7 Days)
📈 Recent Earnings: 2026-05-26
Transaction Date Mar 17, 2026 | | |
| | |
📊 Valuation & Analyst Info
Fair Value: $93.46 (+174.2% undervalued vs current price)
P/E Ratio: 36.3 (1.1x above Biotechnology avg (17.2)) (0.4x above Healthcare avg (26.3))
Analyst Consensus: Buy
Price Target: $68.40 (Low: $30.00 | High: $100.00 | Median: $67.00)
📰 Recent News (Last 7 Days)
📈 Recent Earnings: 2026-05-04
⚠️ Important Disclaimers
Investment Disclaimer: This content is for informational purposes only and should not be considered investment advice.
Data Accuracy: All information is sourced from SEC filings and third-party data providers. Errors or omissions may occur.
Market Risks: Past insider buying activity does not guarantee future performance.
Professional Advice: Consult with qualified financial professionals before making any investment decisions.